Category: Critical Care
Keywords: VAPI, acute respiratory failure, vaping, e-cigarettes, e-hookah, juul, pulmonary disease, acute lung diease, ARDS (PubMed Search)
The U.S. is currently experiencing an epidemic of a severe lung disease termed Vaping-Associated Pulmonary Illness (VAPI), with over 500 cases and 7 deaths across 38 states and 1 U.S. territory since July 2019.
The clinical presentation of VAPI varies --
Treatment is supportive +/- steroids --
Bottom Line: Include vaping-associated pulmonary illness in your differential for patients presenting with acute lung disease.
Background: The use of electronic nicotine delivery systems, also known as e-cigarettes or vape pens, has risen precipitously since their introduction in 2006. They heat a liquid that can contain nicotine, THC/CBD, flavors and/or other additives, producing an aersol that is inhaled by users.
They have been marketed as a way to quit smoking, and as being safer than cigarettes. The U.S. is, however, currently experiencing an epidemic of a severe lung disesae termed Vaping-Associated Pulmonary Illness, with over 500 cases and 7 deaths across 38 states and 1 U.S. territory.
Per data obtained by the CDC:
CDC Emergency Preparedness & Response: "Severe Pulmonary Disease Associated with Using E-Cigarette Products" https://emergency.cdc.gov/han/han00421.asp